Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib
Abstract Background/Aim Lenvatinib, a multikinase inhibitor, has become a second-line treatment 15-eg1053cl option for unresectable liver cancer, while its monotherapy response rate is limited.Hence, we aim to investigate whether one of the epigenetic inhibitors will be synthetic lethal with Lenvatinib in liver cancer cells.Materials and Methods We